Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Roxanne E. Baumgartner is active.

Publication


Featured researches published by Roxanne E. Baumgartner.


Journal of Immunology | 2000

Plasmid Vaccine Expressing Granulocyte-Macrophage Colony-Stimulating Factor Attracts Infiltrates Including Immature Dendritic Cells into Injected Muscles

Diana Haddad; Jayanthi Ramprakash; Martha Sedegah; Yupin Charoenvit; Roxanne E. Baumgartner; Sanjai Kumar; Stephen L. Hoffman; Walter R. Weiss

Plasmid-encoded GM-CSF (pGM-CSF) is an adjuvant for genetic vaccines; however, little is known about how pGM-CSF enhances immunogenicity. We now report that pGM-CSF injected into mouse muscle leads to a local infiltration of potential APCs. Infiltrates reached maximal size on days 3 to 5 after injection and appeared in several large discrete clusters within the muscle. Immunohistological studies in muscle sections from mice injected with pGM-CSF showed staining of cells with the macrophage markers CD11b, Mac-3, IAd/Ed and to the granulocyte marker GR-1 from day 1 through day 14. Cells staining with the dendritic cell marker CD11c were detected only on days 3 to 5. Muscles injected with control plasmids did not stain for CD11c but did stain for CD11b, Mac-3, IAd/Ed, and GR-1. No staining was observed with the APC activation markers, B7.1 or CD40, or with markers for T or B cells. These findings are consistent with the infiltrating cells in the pGM-CSF-injected muscles being a mixture of neutrophils, macrophages, and immature dendritic cells and suggest that the i.m. APCs may be enhancing immune responses to coinjected plasmid Ags. This hypothesis is supported by data showing that 1) separation of injections with pGM-CSF and Ag-expressing plasmid into different sites did not enhance immune responses and 2) immune enhancement was associated with the presence of CD11c+ cells in the infiltrates. Thus, pGM-CSF enhancement may depend on APC recruitment to the i.m. site of injection.


Transplantation | 2001

Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates.

Eric A. Elster; He Xu; Douglas K. Tadaki; Sean P. Montgomery; Linda C. Burkly; Justin D. Berning; Roxanne E. Baumgartner; Frank Cruzata; Richard Marx; David M. Harlan; Allan D. Kirk

BACKGROUND Allogeneic skin transplantation remains a rigorous test of any immune intervention designed to prevent allograft rejection. To date, no single, clinically available immunosuppressant has been reported to induce long-term primary skin allograft survival in primates. We have previously shown that treatment with the humanized CD154-specific monoclonal antibody, humanized 5C8 (hu5C8), induces long-term renal allograft survival in nonhuman primates. In this study, we evaluated the efficacy of hu5C8 in preventing primary skin allograft rejection in rhesus monkeys. METHODS Ten rhesus monkeys were transplanted with full-thickness skin allografts mismatched at both class I and class II major histocompatibility loci. Of these, two were given no treatment, five were treated with hu5C8 alone, and three received hu5C8 combined with whole blood donor-specific transfusion (DST). All recipients also received skin autografts for comparison. Animals were followed by inspection, serial biopsy, mixed lymphocyte culture, and alloantibody determination. RESULTS Treatment with hu5C8 alone or hu5C8 plus DST greatly prolonged allograft survival. Rejection occurred in the untreated group within 7 days. Mean allograft survival in the monotherapy hu5C8 group was >236 days and in the DST group was >202 days; these differences were not significant. Rejection eventually occurred in most animals. Allograft survival was not correlated with the development of T cell hyporesponsiveness in mixed lymphocyte culture. Rejection was not predicted by the development of donor-specific alloantibody. CONCLUSION These results show that treatment with the CD154-specific monoclonal antibody, hu5C8, greatly delays the onset of acute skin allograft rejection.


Transplantation | 2001

Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys.

Bernard Hausen; Jochen Klupp; U. Christians; John P. Higgins; Roxanne E. Baumgartner; L. Hook; Stuart Friedrich; Abbie Celnicker; Randall E. Morris

BACKGROUND Recent studies have shown some efficacy using monotherapy with monoclonal antibodies (mAb) against CD80 and CD86 receptors after life-supporting renal transplantation in non-human primates. Our study was designed to evaluate the efficacy of combinations of the same mAbs with either microemulsion cyclosporine (CsA) or steroids. METHODS Unilateral renal transplantation was performed in 16 blood group-matched and MLR-mismatched cynomolgus monkeys that were assigned to four different treatment groups. All monkeys in groups I, II, and IV were treated with the combination of a CD80 (h1F1) and CD86 (h3D1) mAb given at 20 mg/kg each preoperatively, then 5 mg/kg at weekly intervals starting postoperative (po) day 0 until poday 56 (9 doses). In group I the animals (n=4) were treated with mAbs only. In group II (n=4) mAbs were combined with a CsA regimen adjusted daily to maintain target 24 hr trough levels of 150-300 ng/ml CsA for poday 0 to poday 56. In group III (n=4) the animals received CsA monotherapy according to the same regimen as group II. In group IV methylprednisone was administered at 2 mg/kg IV on poday 0-2, then at 0.5 mg/kg/day prednisone per gavage that was and tapered to 0.2 mg/kg/day on which they were maintained until poday 56. All animals were off all immunosuppressive treatment after poday 56 and were then followed until poday 119. RESULTS The mean survival of groups I-IV was 74 (range 9-119 days), 113 (96-119 days), 39 (22-71 days), and 79 days (6 to 119), respectively. All animals in group I showed clinical evidence of acute severe rejection (fever, creatinine increase, anuria) within the first week posttransplant, including those that retained renal function until poday 119. Only one animal in group II had a moderate clinical rejection during the treatment period and three of four animals survived the intended follow-up period. All animals in group III had multiple biopsy proven or severe clinical rejection episodes within the first 21 days and only one animal survived beyond poday 40. Moderate or severe acute rejection was diagnosed in three of four animals of group IV within the first 28 days post transplant and only one animal survived until poday 119. CONCLUSION Our data show that combining a calcineurin inhibitor or prednisone with mAbs designed to block costimulatory signals does not antagonize the immunosuppressive efficacy of these mAbs. In addition, combining CsA with mAbs directed against the CD80 and CD86 receptors significantly prolongs graft survival when compared to CsA monotherapy. Therefore clinical trials of humanized mAbs to CD80 and CD86 used in combination with conventional immunosuppression can be considered.


World Congress of the Transplantation Society | 2001

Primate skin allotransplantation with anti-CD154 monotherapy.

Eric A. Elster; He Xu; Douglas K. Tadaki; Linda C. Burkly; Justin D. Berning; Roxanne E. Baumgartner; Francis Cruzata; Noelle Patterson; David M. Harlan; Allan D. Kirk


Microbial Pathogenesis | 2002

Evidence for the requirement of T cell costimulation in the pathogenesis of natural Pneumocystis carinii pulmonary infection.

Roxanne E. Baumgartner; Pamela J. Durant; Yvonne Van Gessel; Suchismita Chattopadhyay; Richard L. Beswick; Douglas K. Tadaki; Mark E. Lasbury; Chao Hung Lee; Peter J. Perrin; Kelvin P. Lee


Transplantation | 2000

PRIMARY SKIN ALLOGRAFT ACCEPTANCE WITH ANTI-CD154 IN A NON-HUMAN PRIMATE MODEL.: Abstract# 493 Poster Board #-Session: P133-II

Eric A. Elster; He Xu; Linda C. Burkly; Justin D. Berning; Roxanne E. Baumgartner; Robert L. Kampen; Noelle B. Patterson; Douglas K. Tadaki; David M. Harlan; Allan D. Kirk


Transplantation Proceedings | 2001

Primate skin allotransplantation with anti-CD154 monotherapy 1 1 The views expressed in this article

Eric A. Elster; Haisong Xu; Douglas K. Tadaki; Linda C. Burkly; Justin D. Berning; Roxanne E. Baumgartner; Francis Cruzata; Noelle Patterson; David M. Harlan; Allan D. Kirk


Transplantation | 2000

COADMINISTRATION OF EITHER MICROEMULSION CYCLOSPORINE OR STEROIDS WITH HUMANIZED MONOCLONAL ANTIBODIES AGAINST THE B7-1 AND B7-2 EPITOPES SUCCESSFULLY PROLONG ALLOGRAFT SURVIVAL AFTER LIFE SUPPORTING RENAL TRANSPLANTATION IN CYNOMOLGUS MONKEYS.: Abstract# 47

Bernard Hausen; Jochen Klupp; L. Hook; Uwe Christians; Roxanne E. Baumgartner; Stuart Friedrich; Abbie Celnicker; Randall E. Morris


Transplantation | 2000

PRIMATE ALLOTRANSPLANTATION USING COSTIMULATION BLOCKADE.: Abstract# 1156

Allan D. Kirk; Douglas K. Tadaki; He Xu; Eric A. Elster; Linda C. Burkley; Abbie Cheryl Celniker; D. Scott Batty; Roxanne E. Baumgartner; Justin D. Berning; John H. Fechner; Robert L. Kampen; Stuart J. Knechtle; Noelle B. Patterson; S. John Swanson; David M. Harlan


Transplantation | 1999

RHESUS RENAL ALLOGRAFTS CONTAIN NON-DESTRUCTIVE ACTIVATED LYMPHOCYTIC INFILTRATES FOLLOWING ANTI-CD154 THERAPY.

Roxanne E. Baumgartner; Noelle B. Patterson; Justin D. Berning; Linda C. Burkly; Rhonda L. Germond; David M. Harlan; Robert L. Kampen; Douglas K. Tadaki; Sharda G. Sabnis; Allan D. Kirk

Collaboration


Dive into the Roxanne E. Baumgartner's collaboration.

Top Co-Authors

Avatar

Douglas K. Tadaki

Naval Medical Research Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David M. Harlan

University of Massachusetts Medical School

View shared research outputs
Top Co-Authors

Avatar

Justin D. Berning

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eric A. Elster

Uniformed Services University of the Health Sciences

View shared research outputs
Top Co-Authors

Avatar

He Xu

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Noelle B. Patterson

Naval Medical Research Center

View shared research outputs
Top Co-Authors

Avatar

Robert L. Kampen

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge